Pharma Focus Asia

Thermo Fisher Constructs New cGMP Plasmid DNA Manufacturing Facility in California

Introduction:
Thermo Fisherplans to construct a new manufacturing facility for the production of clinical and commercial capabilities. The facility will be located in Carlsbad, California. The expansion of this facility enhances the commercialisation of plasmid-based medicines and vaccines.

Features:
The facility is constructed with an area covering 67,000-square-foot. The new start-of-art-facility is designed with advanced technologieswhich usesingle-use equipment with up to 1,000L scale, allowing operational efficiencies and operator training with digital connectivity and data visibility.

It also expands commercial and clinical capabilities for plasmid DNA which can be used as a raw material for manufacturing cell and gene therapies for cancer treatments as well as mRNA vaccines. Moreover, the facility not only deals with supply bottleneck for customers, but also helps indelivering robust end-to-end cell and gene therapy capabilities.

It is expected that the new manufacturing facility will complete its construction in the first half of 2021. It is estimated that the new site will create approximately 150 jobs.

Specifications:

NameThermo Fisher Scientific
TypeExpansion
YearQ1 2021

 

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference